Sertraline pharmacokinetics and dynamics in adolescents

J Am Acad Child Adolesc Psychiatry. 2002 Sep;41(9):1037-44. doi: 10.1097/00004583-200209000-00003.

Abstract

Objective: To determine the pharmacokinetics of sertraline in adolescents and assess its effect on a surrogate marker of serotonin transport.

Method: Pharmacokinetic parameters of a single 50-mg dose of sertraline were determined in 10 adolescents. Steady-state withdrawal kinetics were determined in 12 adolescents taking 50 mg/day and in 6 adolescents taking 100 to 150 mg/day. Platelet serotonin reuptake was measured before and after 2 weeks of daily 50-mg dosing.

Results: The mean steady-state half-life of 50 mg was significantly shorter (15.3 +/- 3.5 hours) than the single-dose half-life (26.7 +/- 5.2 hours; t = 6.4, p < .001) and the steady-state half-life at 100 to 150 mg/day (20.4 +/- 3.4 hours; t = 2.9, p = .01). Platelet serotonin reuptake was inhibited by 61 +/- 15% after approximately 2 weeks of sertraline 50 mg/day.

Conclusions: The half-life of sertraline 50 mg becomes significantly shorter from the initial dose to steady-state, and many adolescents may benefit from twice-per-day dosing. The steady-state half-life increases as the dose increases. The moderate levels of platelet reuptake inhibition at 50 mg/day indicate that most adolescents may need sertraline doses higher than 50 mg/day to attain a therapeutic response.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent / physiology*
  • Blood Platelets / metabolism
  • Dose-Response Relationship, Drug
  • Female
  • Half-Life
  • Humans
  • Male
  • Selective Serotonin Reuptake Inhibitors / pharmacokinetics*
  • Serotonin / metabolism
  • Sertraline / pharmacokinetics*

Substances

  • Serotonin Uptake Inhibitors
  • Serotonin
  • Sertraline